Mounjaro vs Wegovy: Which GLP-1 Medication Is Right for You?

The Core Difference: One Receptor vs Two

The fundamental distinction between Mounjaro and Wegovy comes down to mechanism. Wegovy (semaglutide) is a selective GLP-1 receptor agonist — it activates one receptor. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist — it activates two receptors simultaneously.

GLP-1 (glucagon-like peptide-1) is the shared mechanism: both drugs slow gastric emptying, reduce appetite through brain GLP-1 receptors, and stimulate insulin secretion in a glucose-dependent manner.

What tirzepatide adds is GIP (glucose-dependent insulinotropic polypeptide) agonism. GIP is an incretin hormone secreted in the small intestine in response to fat and carbohydrate intake. GIP receptors are found in adipose tissue, the brain, the pancreas, and the gut. Adding GIP agonism appears to:

• Enhance insulin sensitivity beyond what GLP-1 alone achieves
• Produce additional appetite suppression through central nervous system pathways
• Improve lipid metabolism and reduce visceral adiposity
• Potentially improve overall GI tolerability compared to a pure GLP-1 agonist at equivalent efficacy levels

The clinical consequence of this dual mechanism: tirzepatide achieves greater weight loss than semaglutide in head-to-head comparisons, which we'll explore in depth below.

Clinical Trial Data: SURMOUNT-1 vs STEP-1

The landmark trials for each medication provide the best comparison of their efficacy — though importantly, these are separate trials with different populations, not direct head-to-head studies.

SURMOUNT-1: Tirzepatide's Landmark Trial

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without type 2 diabetes. Participants were randomized to tirzepatide 5mg, 10mg, or 15mg, or placebo, once weekly for 72 weeks.[1]

Key results:

• 5mg: Mean weight loss of 15.0% of body weight
• 10mg: Mean weight loss of 19.5% of body weight
• 15mg: Mean weight loss of 20.9% (completer analysis: 22.5%) of body weight
• Placebo: Mean weight loss of 3.1%
• At the 15mg dose, 57% of participants achieved ≥20% weight loss and 36% achieved ≥25% weight loss

These numbers represent a step-change in what was previously thought achievable with a once-weekly injectable. The 22.5% average at 15mg approaches the results seen with bariatric surgery.[1]

STEP-1: Semaglutide's Landmark Trial

STEP-1 enrolled 1,961 adults with similar eligibility criteria and followed them for 68 weeks on semaglutide 2.4mg or placebo. Results:

• Mean weight loss of 14.9% in the semaglutide group
• 86.4% of participants achieved ≥5% weight loss
• 69.1% achieved ≥10% weight loss
• 50.5% achieved ≥15% weight loss
• Placebo: 2.4% weight loss[2]

Important Caveat: These Aren't Head-to-Head

SURMOUNT-1 and STEP-1 were separate trials with slightly different patient populations, durations (72 vs 68 weeks), and methodologies. The numbers can't be directly compared with full confidence. However, a network meta-analysis published in The Lancet in 2022 — which did attempt to pool these trials — concluded that tirzepatide 15mg was associated with greater weight loss than semaglutide 2.4mg.[3] A direct head-to-head trial (SURMOUNT-5) comparing the two drugs was completed in 2025, confirming tirzepatide's greater efficacy at maximum doses.

Full Head-to-Head Comparison Table

Cost: Mounjaro Is Actually Cheaper at List Price

Counterintuitively, Mounjaro/Zepbound has a slightly lower list price than Wegovy in the US market. However, list price rarely reflects what patients actually pay — insurance coverage and manufacturer coupons matter far more.

Mounjaro / Zepbound Costs

• Zepbound (obesity) list price: ~$1,050–$1,200/month depending on dose
• Mounjaro (diabetes) list price: ~$1,000–$1,100/month
• Lilly Savings Card (Zepbound): Eligible commercially insured patients may pay as little as $25/month
• Without insurance: Lilly's direct program has offered Zepbound at reduced rates (~$550/month) for patients without coverage
• With T2D + Mounjaro: Often well-covered; similar to Ozempic for diabetes

Wegovy Costs

• List price: ~$1,300–$1,400/month
• Novo Nordisk Savings Program: Commercially insured patients may pay as little as $0–$25/month
• Medicare: Covered under Part D for cardiovascular risk reduction (SELECT trial indication) in eligible patients
• Without insurance: Full list price; no robust discount program comparable to Lilly's Zepbound offering

Bottom line on cost: for patients with commercial insurance that covers anti-obesity medications, savings cards bring both drugs to comparable out-of-pocket costs. Without insurance, Zepbound has a modest list price advantage, and Lilly's direct pricing program provides a meaningful option for uninsured patients.

Insurance Coverage: The Evolving Landscape

Insurance coverage for anti-obesity medications has been the central access challenge for both drugs. The landscape is improving but remains inconsistent:

Factors favoring Wegovy coverage

• The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults with established cardiovascular disease — independent of weight loss[4]
• This CV outcome data led to a new FDA indication for Wegovy in cardiovascular risk reduction, unlocking Medicare Part D coverage
• Some commercial insurers have added Wegovy as a covered benefit for patients meeting the SELECT criteria

Factors favoring Mounjaro coverage

• Mounjaro (tirzepatide for diabetes) is typically covered when prescribed for T2D
• Zepbound's growing market share and competitive pricing has pushed more insurers to add it
• Lilly's direct-to-consumer pricing has been more aggressive than Novo Nordisk's for cash-pay patients

For both drugs, the fastest path to affordable access typically runs through one of: (1) an employer-sponsored plan that explicitly covers anti-obesity medications, (2) a T2D diagnosis and the appropriate branded diabetes version (Ozempic or Mounjaro), or (3) an obesity medicine specialist who can navigate prior authorization processes.

Side Effect Comparison

Both drugs share the same core GI side effect profile — nausea, constipation, diarrhea, vomiting — because both activate GLP-1 receptors in the gut. The data on how they compare in tolerability is nuanced:

GI Side Effects

SURMOUNT-1 reported nausea in approximately 33% of participants on tirzepatide 15mg, compared to 44% on semaglutide 2.4mg in STEP-1. This has led some clinicians to view tirzepatide as somewhat better tolerated, though trial design differences limit direct comparison. The prevailing clinical interpretation: tirzepatide achieves more weight loss with roughly comparable or slightly fewer GI side effects than semaglutide at maximum doses.

For detailed strategies on managing GI side effects for either medication, see our complete semaglutide side effects guide — most management approaches apply to both drugs.

Heart Rate Increase

Both semaglutide and tirzepatide can cause small increases in resting heart rate (approximately 2–4 bpm on average). This is a class effect of GLP-1 receptor agonism and is generally well-tolerated. Patients with pre-existing tachycardia or arrhythmias should discuss this with their cardiologist.

Thyroid C-Cell Risk

Both drugs carry the same black-box warning about thyroid C-cell tumors based on rodent studies. Neither has shown this effect in human trials. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

Pancreatitis Risk

Both carry similar pancreatitis warnings. The absolute risk is low (approximately 0.1–0.3% in trials) but real. Severe abdominal pain on either drug requires prompt medical evaluation.

Who Is the Better Candidate for Each Drug?

Consider Mounjaro/Zepbound if:

• You want the maximum available weight loss from a once-weekly injectable — the trial data is clear that tirzepatide at 15mg outperforms semaglutide 2.4mg
• You have type 2 diabetes — Mounjaro is approved for T2D and shows superior glucose-lowering versus semaglutide in head-to-head trials
• You need significant weight loss (40+ lbs) and want to use the most potent available pharmacotherapy
• You have insulin resistance, metabolic syndrome, or PCOS — the dual GIP/GLP-1 mechanism shows particular promise in these conditions
• You've tried semaglutide and had insufficient weight loss response — switching to tirzepatide can produce additional significant weight loss
• You're uninsured and can access Zepbound's direct pricing program (~$550/month)

Consider Wegovy if:

• You have established cardiovascular disease — the SELECT trial gives Wegovy a unique FDA-approved indication for CV risk reduction, which also unlocks Medicare coverage
• Your insurance specifically covers Wegovy but not Zepbound (check your formulary)
• You have a history of GI issues that may limit tolerance — the overall side effect burden per weight loss unit may be slightly higher with tirzepatide based on some analyses
• You prefer the more established data set — semaglutide has been on the market longer with more real-world outcomes data
• Your prescriber has more experience managing semaglutide (which is simply more widely prescribed)

Availability and Supply

Both Mounjaro and Wegovy have experienced supply shortages as demand has dramatically outpaced manufacturing capacity. The supply situation has improved substantially from the 2022–2024 peak shortage period, but availability can still vary by pharmacy and region.

Compounded versions of both semaglutide and tirzepatide emerged during shortage periods. The FDA removed most compounded semaglutide from the market in early 2025 after ruling the shortage was resolved. Compounded tirzepatide remains in a more complex regulatory situation. Compounded GLP-1 medications carry real quality and consistency risks — if you use them, work with a reputable compounding pharmacy and understand what you're getting.

What Happens When You Switch?

A common clinical question is: what happens if I try one drug first and want to switch? Real-world data on switching is encouraging:

• Patients switching from semaglutide to tirzepatide typically experience additional weight loss on tirzepatide, even after plateauing on semaglutide
• The reverse switch (tirzepatide to semaglutide) is less common clinically but generally involves maintaining some of the lost weight at therapeutic semaglutide doses
• Switching typically involves restarting at the lowest dose of the new medication and titrating up, similar to starting fresh

If you're not achieving your desired results on one medication and have been at maximum dose for at least 12 weeks, it's worth discussing a switch with your prescriber.

The Verdict: Which Is Better?

If the question is purely which produces more weight loss, the answer is Mounjaro/Zepbound — the data is consistent and compelling. The dual GIP/GLP-1 mechanism produces meaningfully greater weight loss than GLP-1 alone at current approved maximum doses.

But "better" in medicine is always patient-specific. Wegovy's cardiovascular outcomes data, more established long-term safety record, and specific insurance pathways make it the better fit for many patients. The right choice depends on your medical history, insurance situation, weight loss goals, and your prescriber's clinical judgment.

Both drugs represent transformative advances in obesity treatment. Either is a reasonable choice for appropriate candidates. The goal is getting on one of these medications with proper medical supervision — not spending months paralyzed by the comparison.

Related Articles

• Semaglutide Weight Loss Timeline: Week by Week Guide
• Ozempic vs Wegovy: Complete Cost and Dosage Comparison
• Semaglutide Dosage Guide: Complete Titration Schedule
• Managing Semaglutide Side Effects: Complete Guide

References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
3. Shi Q, et al. Comparative effects of glucagon-like peptide-1 receptor agonists and other new diabetes drugs on body weight: systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2022;10(9):621-631.
4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.